Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

J. Zhou; Y. L.A. Chau; J. W. Yoo; S. Lee; K. Ng; E. C. Dee; T. Liu; A. K.C. Wai; Q. Zhang; G. Tse

doi:10.1016/j.clon.2022.03.006

Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

J. Zhou, Y. L.A. Chau, J. W. Yoo, S. Lee, K. Ng, E. C. Dee, T. Liu, A. K.C. Wai, Q. Zhang, G. Tse

Research output: Contribution to journal › Letter › peer-review

9 Citations (Scopus)

Original language	English
Pages (from-to)	e316-e317
Journal	Clinical Oncology
Volume	34
Issue number	7
DOIs	https://doi.org/10.1016/j.clon.2022.03.006
Publication status	Published - Jul 2022
Externally published	Yes

Access to Document

10.1016/j.clon.2022.03.006

Cite this

Zhou, J., Chau, Y. L. A., Yoo, J. W., Lee, S., Ng, K., Dee, E. C., Liu, T., Wai, A. K. C., Zhang, Q., & Tse, G. (2022). Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses. Clinical Oncology, 34(7), e316-e317. https://doi.org/10.1016/j.clon.2022.03.006

@article{62a562f5ded5444aacd45fac27cc479b,

title = "Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses",

author = "J. Zhou and Chau, {Y. L.A.} and Yoo, {J. W.} and S. Lee and K. Ng and Dee, {E. C.} and T. Liu and Wai, {A. K.C.} and Q. Zhang and G. Tse",

year = "2022",

month = jul,

doi = "10.1016/j.clon.2022.03.006",

language = "English",

volume = "34",

pages = "e316--e317",

number = "7",

}

Zhou, J, Chau, YLA, Yoo, JW, Lee, S, Ng, K, Dee, EC, Liu, T, Wai, AKC, Zhang, Q & Tse, G 2022, 'Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses', Clinical Oncology, vol. 34, no. 7, pp. e316-e317. https://doi.org/10.1016/j.clon.2022.03.006

TY - JOUR

T1 - Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors

T2 - A Propensity Score Matched Study with Competing Risk Analyses

AU - Zhou, J.

AU - Chau, Y. L.A.

AU - Yoo, J. W.

AU - Lee, S.

AU - Ng, K.

AU - Dee, E. C.

AU - Liu, T.

AU - Wai, A. K.C.

AU - Zhang, Q.

AU - Tse, G.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85131828161&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2022.03.006

DO - 10.1016/j.clon.2022.03.006

M3 - Letter

C2 - 35321832

AN - SCOPUS:85131828161

SN - 0936-6555

VL - 34

SP - e316-e317

JO - Clinical Oncology

JF - Clinical Oncology

IS - 7

ER -

Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

Access to Document

Other files and links

Cite this